Search the Newsreel

Caribou Biosciences Q2 Results: Net loss narrows to $24.3 million

Caribou Biosciences reported a narrowed net loss of $24.3 million in Q2 2026, significantly improving from $54.1 million in Q2 2025, beating EPS estimates. This was primarily due to a sharp decline in operating expenses and cost-cutting measures. However, quarterly sales missed analyst forecasts, …

Caribou Biosciences, Inc. reports results for the quarter ended June 30 - Earnings Summary

Caribou Biosciences, Inc. has released its earnings summary for the quarter that ended on June 30. The article is a brief announcement from Reuters, indicating that a full report is available to subscribers of TradingView.

Cellectar Biosciences (CLRB) ownership: Bleichroeder group reports 9.99% equity stake

Bleichroeder entities, led by Bleichroeder LP and Andrew Gundlach, have reported a 9.99% equity stake in Cellectar Biosciences (CLRB), amounting to 808,300 common shares. Bleichroeder LP, a registered investment adviser, holds these shares for various advisory clients, granting them sole voting and dispositive power …

Ensysce Biosciences (ENSC) widens loss as cash falls, adds funding via Cy Biopharma deal

Assembly Biosciences (ASMB) boosts cash to $320M and narrows loss

Assembly Biosciences: Q2 Earnings Snapshot

Deerfield group discloses 2.88% Cogent Biosciences (COGT) position in amended 13G

A group of Deerfield entities and James E. Flynn have filed an amended Schedule 13G, revealing a collective beneficial ownership of 5,006,104 shares of Cogent Biosciences (COGT) common stock, which represents 2.88% of the outstanding class. The filing indicates shared voting and dispositive power …

Artisan Partners group (TWST) discloses 4.8M-share position in Twist Bioscience

Artisan Partners Asset Management Inc. and its affiliates have disclosed a beneficial ownership of 4,802,017 common shares, representing a 7.7% stake, in Twist Bioscience Corporation (TWST). This position is held on behalf of Artisan Partners Limited Partnership's discretionary clients, with shared voting power over …

Assembly Biosciences Projects Operations Funded Into 2029 With $75M Gilead Payment Due

Assembly Biosciences reported its Q2 2026 financial results, revealing a projected cash runway into 2029, bolstered by a recent $115 million financing and an anticipated $75 million payment from Gilead. The company is advancing its ABI-6250 program into Phase 2 studies for cholestatic liver …

Daré Bioscience launches Flora Sync, its first directly commercialized product

Daré Bioscience (NASDAQ: DARE) reported Q2 2026 revenue of $0.19 million, a net loss of $3.0 million, and $12.6 million in cash and equivalents. The company announced the launch of Flora Sync LF5, its first directly commercialized product, which began generating revenue in July …

Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances

Daré Bioscience reported its Q2 2026 financial results, highlighting significant progress in its multi-product women's health strategy. The company launched Flora Sync LF5 and is preparing for national dispensing of DARE to PLAY Sildenafil Cream, expecting initial revenue in Q3 2026. Daré also provided …

Dare Bioscience, Inc. 2026: Revenue $187.55K, EPS ($0.2) — 10-Q Summary

Dare Bioscience, Inc. reported its 2026 quarterly results, with revenue of $187.55K and a net loss of ($2.98M), which is an improvement from the prior year's loss. The company saw revenue growth due to Gates Foundation agreements and the launch of new products and …

Inhibrx Biosciences (INBX) deepens losses but reports pivotal ozekibart and INBRX-106 data

Inhibrx Biosciences (INBX) reported a net loss of $70.1 million for the first half of 2026, with no revenue, while holding $133.3 million in cash and equivalents. Despite the losses, the company advanced its clinical pipeline, with ozekibart achieving a statistically significant progression-free survival …

Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates

Assembly Biosciences, Inc. – Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) – – Completed $115 million gross financing to support advancement of pipeline programs through key development milestones – – GS-1179 (formerly ABI-1179) …

FDA Sets April 2027 Goal Date for Inhibrx's Ozekibart

Inhibrx reported a net loss of $36.7 million in Q2 2026, with R&D expenses at $23.9 million and G&A at $8.3 million. The company secured an amended loan with Oxford Finance for up to $325.0 million, with $100.0 million already funded. The FDA accepted …

Caribou's Single-Dose CAR-T Shows 92% Response in 12 Myeloma Patients

Caribou Biosciences reported its Q2 2026 financial results and provided an update on its CAR-T pipeline. The company's vispa-cel therapy for large B cell lymphoma showed an 82% overall response rate, while CB-011 for multiple myeloma achieved a 92% overall response rate in a …

Solid Biosciences LLC (NASDAQ: SLDB) Share Price, SLDB Stock News, SLDB Share Price & Updates

Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction

Castle Biosciences (NASDAQ: CSTL) raised its full-year outlook after exceeding second-quarter expectations, primarily driven by strong performance from its DecisionDx-Melanoma and TissueCypher tests, along with increased physician adoption. The DecisionDx-Melanoma test continues to be a key growth driver, showing mid- to high-single-digit volume growth, …

Cellectar Biosciences Releases Q2 2026 Financial Results

Cellectar Biosciences (CLRB) reported a wider-than-expected diluted loss of $0.57 per share for Q2 2026, missing analyst estimates. Despite this, the net loss of $6.9M represents an 83.2% improvement year-over-year. The clinical-stage biopharmaceutical company maintains strong analyst support for its oncology pipeline.

Pulse Biosciences (NASDAQ:PLSE) Sets New 1-Year High - Time to Buy?

Pulse Biosciences (NASDAQ:PLSE) stock reached a new 52-week high of $46.03, closing at $46.75, despite reporting weaker-than-expected quarterly results. Analyst sentiment is mixed, with a "Moderate Buy" consensus but an average price target below the current trading price. Institutional investors hold a significant 76.95% …

Citizens cuts Spruce Biosciences stock price target on share dilution

Citizens has lowered its price target for Spruce Biosciences (NASDAQ: SPRB) from $150.00 to $144.00, citing potential share dilution indicated in the company's 10-Q filing, while maintaining a Market Outperform rating. Despite the reduction, the new target still suggests significant upside, though InvestingPro data …

Artelo Biosciences Releases Q2 2026 Financial Results

Artelo Biosciences, Inc. reported a net loss of $2.4M and a loss of $0.89 per share for Q2 2026, marking a significant improvement from the $16.8 per-share loss in Q2 2025. The clinical-stage biopharmaceutical company continues to advance its therapeutic pipeline targeting lipid-signaling pathways, …

Artelo Plans Q4 Trial After ART26.12 Matches Naproxen for Pain

Artelo Biosciences reported its Q2 2026 financial results, with a narrowed net loss of $2.4 million and positive pipeline updates. The company plans a Phase 1 multiple ascending dose study for ART26.12 in Q4 2026, which has shown pain relief comparable to naproxen in …

Morgan Stanley Has Lowered Expectations for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price

Spruce Biosciences (NASDAQ:SPRB) Given New $144.00 Price Target at Citizens Jmp

Citizens Jmp has reduced its price target for Spruce Biosciences (NASDAQ:SPRB) to $144.00 from $150.00 but maintained a "market outperform" rating, indicating a potential upside of nearly 199%. Despite a wider-than-expected quarterly loss of $6.68 per share, analyst sentiment remains largely positive with a …

Artelo Biosciences (ARTL) investors disclose 4.8% stake via Intracoastal warrant

Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC have disclosed a 4.8% beneficial ownership stake in Artelo Biosciences (ARTL) through a warrant held by Intracoastal. This ownership amounts to 173,914 shares of common stock, issuable upon the warrant's exercise, and is based …

Kuros Biosciences erzielt im ersten Halbjahr 2026 Gewinn bei 45 % Umsatzwachstum

Pulse Biosciences stock reaches all-time high at 46.03 USD By Investing.com

Pulse Biosciences Inc. (PLSE) stock hit an all-time high of $46.03, currently trading near its 52-week high of $45.90, despite a recent report of wider-than-expected Q2 2026 losses and lower revenue. The stock has seen a significant 163.78% one-year increase and 216% year-to-date, boosting …

Twist Bioscience stock hits 52-week high at 126.22 USD

Twist Bioscience stock reached a new 52-week high of $126.22, trading just 1% below this peak and marking a remarkable 440% surge from its 52-week low. The company also reported strong fiscal third-quarter 2026 revenues of $118.4 million, exceeding Wall Street estimates, although adjusted …

Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Lexaria Enters a Material Transfer Agreement With PegBio

Lexaria Bioscience Corp. has signed a Material Transfer Agreement (MTA) with PegBio Co., Ltd to evaluate Lexaria's DehydraTECH technology with PegBio's proprietary GLP-1 molecule for the GLP-1 industry. This collaboration aims to enhance the accessibility and effectiveness of PegBio's GLP-1-related drug products, which target …

Earnings call transcript: Cellectar narrows focus on WM as Q2 2026 loss widens

Cellectar Biosciences reported a wider-than-expected Q2 2026 loss of $0.57 per share, but its stock rose in premarket trading due to a stronger cash position and clinical progress for its lead drug, iopofosine I-131, in Waldenstrom’s macroglobulinemia (WM). The company secured up to $140 …

Avoiding Lag: Real-Time Signals in (TYRA) Movement

The article analyzes Tyra Biosciences Inc. (NASDAQ: TYRA), highlighting weak near-term and mid-term sentiment despite a long-term positive outlook. It provides AI-generated institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and support/resistance levels.

Alamar Biosciences, Inc. (ALMR) Q2 2026 Earnings Report - Results, Call & Slides

Alamar Biosciences, Inc. (ALMR) reported its Q2 2026 earnings, beating both EPS and revenue expectations. The company posted an actual EPS of -$0.22 against a consensus of -$0.31, and actual revenue of $29.40 million compared to an expected $25.86 million. The earnings call took …

News by ACCESS Newswire on TradingView, 2026-08-13

Lexaria Bioscience Corp. has announced a Material Transfer Agreement (MTA) with PegBio Co., Ltd to explore Lexaria's DehydraTECH technology with a proprietary PegBio GLP-1 molecule for the GLP-1 industry. This collaboration aims to evaluate the pharmacokinetic performance of the combined technology in animal studies, …

Microbix Biosystems Q3 2026 Earnings Call Transcript